A device manufacturer preparing a 45-patient feasibility study asks three vendors to quote an electronic data capture (EDC) system. Two of the quotes come back with implementation timelines measured in months, a required data management services package, and pricing modeled on patient volumes the study will never reach. The platforms are capable. They were also built for a different kind of trial.
A pharma EDC can technically run a medical device study. It is rarely the right fit, because device studies are smaller, span the full product lifecycle, and leave the manufacturer legally responsible for the evidence, and a platform built for pharmaceutical trials makes each of those harder. The cost of the mismatch shows up in three places: setup time, fees, and control of your own clinical data.
By this point the manufacturer has already made the easy call, that the study needs a real EDC rather than spreadsheets or paper. If you are still weighing that question, the full guide to EDC for medical device trials covers what the software has to do and how to evaluate it. The harder decision is the one that comes next: run the study on a general or pharma-heritage platform that a CRO or an investor already knows, or on a system built specifically for device work. That choice looks like a procurement detail. It quietly sets how much you pay, how long setup takes, and who controls your clinical evidence when the study closes.
Pharmaceutical development moves through defined phases with large enrollment targets and long timelines. Medical device studies follow a different path across the product lifecycle. A team might run a first-in-human (FIH) study, move to a feasibility study, then a pivotal study, and continue generating evidence through post-market clinical follow-up (PMCF) for years after launch. Enrollment is usually smaller. The cadence is more iterative. And the work does not stop at approval, because clinical evidence keeps getting reused across submissions, post-market activities, and the next program.
Those structural differences change what the software has to do. Device studies mix eCRF data with patient-reported outcomes, adverse events tied to device deficiencies, and per-procedure observations that a drug-trial data model never anticipated. Handling that well is a clinical data management problem, not just a form-building one, and the gap between a general platform and one that understands device workflows is spelled out in this breakdown of what a clinical data management system does for device trials.
A pharma-first platform treats a 40-patient device study with the same operational weight it applies to a 3,000-patient drug trial. That weight is not free. It arrives as configuration effort, validation burden, and a services layer priced for organizations with clinical operations departments most device teams do not have. Lean teams end up paying for scale they will never use, and spending weeks bending a general-purpose tool into something that resembles a device workflow. The platform's origins do not stay in the background. They show up every time the study needs something the software was not designed to do.
Under ISO 14155 and EU MDR, responsibility for clinical evidence sits with the manufacturer, not with the CRO and not with the software vendor. That accountability does not transfer when a study is outsourced, even though control of the data often does.
Here is where the pharma model quietly creates risk. In large drug research, sponsors run dedicated data management organizations, and the CRO relationship is built around handing operations to a partner with deep infrastructure. The regulatory framework for medical devices keeps sponsor responsibility closer to home, yet device manufacturers, especially early and lean ones, frequently assume the pharma arrangement is the only option. So they let a CRO stand up the study in a CRO-owned system, or they license a pharma platform and route access through a services team. Visibility drops. When the study ends, the data lives somewhere the manufacturer does not fully control, in a format that is hard to extract, sometimes behind fees or access terms set by someone else.
That becomes a problem later rather than sooner. The feasibility data a team collected two years ago is exactly what a regulator wants to see during a submission, or what a notified body expects during PMCF. If that evidence is locked in a system the manufacturer cannot freely access, the team is reconstructing history under deadline pressure. Owning the evidence from the first study is what prevents that scramble.
For a lean team, control and simplicity are not opposites, and that is the real weight behind the decision. A manufacturer can stay in control of its own data, keep full visibility into an ongoing study, and still work with a CRO to execute. Ownership is about where the evidence lives and who can reach it, not about who runs the day-to-day.
Vendors selling general-purpose or pharma-heritage systems often answer the device question with a single word: configurable. The platform can be set up for device studies. It can support smaller enrollments. It can be adapted.
Adaptation has a price, and device teams tend to underestimate it. Configuring a pharma platform to match how a device eCRF should actually be built means design work, validation work, and often outside consultants. Every hour spent making a general tool behave like a device tool is an hour not spent on the study. And the result still carries the platform's original assumptions underneath, which surface again the next time the team needs a device-specific workflow the software was never designed to handle.
Bernafon lived this progression. The hearing aid manufacturer moved from Excel to a free EDC platform that turned out to be frustrating and increased the time spent managing data. After moving to a device-built platform, the team reduced study setup and management time and cut data export effort to almost nothing. As Barbara Simon, lead clinical audiologist at Bernafon, put it: "We can easily access our data without a huge fuss, and it is now super easy and flexible for us to create each page of our eCRF."
The real alternative most teams weigh is not paper versus software. That comparison against paper and spreadsheet workflows is usually settled before serious evaluation begins. The live decision is a device-built platform versus a pharma one the team will spend months adapting, and that is where the tradeoff actually bites.
Enterprise pharma platforms are implemented in quarters. That timeline is defensible when the study is a multi-year global program with a dedicated project team. It is a poor match for a device manufacturer that needs to enroll its first patients in weeks and cannot afford a months-long build before data collection begins.
Loop Medical set up a new international study in a couple of weeks without anyone working on it full-time, and gained real-time access to study data that saved both time and money. Alison Moran, clinical affairs manager at Loop Medical, described the result simply: "It's made data collection faster and easier and removed headaches." Kerecis had been running simple studies in Excel that were time-consuming and not compliant with EU MDR. After switching to a device-built platform, the team achieved full data compliance in both the United States and Europe and eliminated manual data entry entirely.
None of those outcomes required an enterprise implementation. They required a platform whose defaults already matched device studies, so the team could start collecting compliant data quickly rather than spending the first quarter configuring the tool. For a lean team, that difference in timeline often decides the whole question.
The decision is not that pharma platforms are bad software. They are strong tools for the trials they were designed to run. The decision is whether that fit matches your job, which is different: generate compliant clinical evidence across the device lifecycle, keep control of that evidence, and reuse it from feasibility through PMCF without rebuilding it each time.
Weighed against that job, a device-built platform carries study designs, eCRF and ePRO structures, and adverse event workflows shaped for medical devices rather than adapted from drug research. It keeps the manufacturer's data accessible and portable, without CRO-controlled access or lock-in, and it supports the full arc from FIH through post-market rather than a single phase. It avoids the configuration tax and enterprise overhead that come with retrofitting a pharma system. If you are still comparing vendors head to head, the evaluation framework walks through the questions to ask before you sign.
Two years from now, when a regulator asks for the data behind a claim, the manufacturer that owns its evidence in a device-built system answers in an afternoon. The one whose data sits inside a pharma platform it never fully controlled starts a longer conversation. That is the choice, made early, that decides which position you are in.
Can you use a pharma EDC for a medical device study? Technically yes. The platform will capture data, but it has to be configured to fit device workflows, which adds setup time, validation work, and cost, and it often leaves the manufacturer with less direct control of the data.
What makes an EDC purpose-built for medical devices? A device-built EDC ships with study designs for first-in-human, feasibility, pivotal, and PMCF work, eCRF and ePRO structures shaped for device data, and adverse event handling tied to device deficiencies, aligned out of the box to ISO 14155, EU MDR, and 21 CFR Part 11 rather than configured to reach them.
Who is responsible for the clinical data in a medical device study? Under ISO 14155 and EU MDR, the manufacturer is responsible for its clinical evidence, even when a CRO runs the study. A device-built platform keeps that data accessible and portable, without CRO-controlled access or vendor lock-in.
How long does it take to set up a study in a device-built EDC? Weeks, not the quarters typical of enterprise pharma implementations, because the platform's defaults already match device studies rather than needing to be configured to fit them.
If you are evaluating an EDC for a device study, these related guides go deeper on the specifics:
Greenlight Guru Clinical was built for the device side of that decision, from eCRF and ePRO capture through adverse event reporting and PMCF, across the full clinical data management workflow a device program runs on. If you are weighing a pharma platform against a device-built one, put your own study design in front of both. That is the fastest way to see the difference. Reach out to the Greenlight Guru Clinical team to request a demo, bring the workflows you actually need to run, and see how a purpose-built system handles them. If you would rather start with a conversation about where you are in your clinical program, get in touch and we will walk through where a device-built platform fits.